Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
Authors
Keywords
Drug-induced obesity, Mechanisms, Metabolic syndrome, Antipsychotics, Therapy
Journal
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Volume 40, Issue 11, Pages 1165-1174
Publisher
Springer Nature
Online
2017-06-28
DOI
10.1007/s40618-017-0719-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain
- (2017) Alessandro Rimessi et al. NEUROPSYCHOPHARMACOLOGY
- Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
- (2017) Stephanie A. Flowers et al. PHARMACOTHERAPY
- Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race
- (2017) Thomas J. Moore et al. JAMA Internal Medicine
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- An update of safety of clinically used atypical antipsychotics
- (2016) L. Orsolini et al. Expert Opinion On Drug Safety
- National trends in off-label use of atypical antipsychotics in children and adolescents in the United States
- (2016) Minji Sohn et al. MEDICINE
- Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience
- (2016) Caroline Ménard et al. NEUROPSYCHOPHARMACOLOGY
- Role of Adiposity-Driven Inflammation in Depressive Morbidity
- (2016) Lucile Capuron et al. NEUROPSYCHOPHARMACOLOGY
- Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
- (2015) Luc Van Gaal et al. DIABETES CARE
- Glucocorticoid Excess Increases Hepatic 11β-HSD-1 Activity in Humans: Implications in Steroid-Induced Diabetes
- (2015) Simmi Dube et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
- (2015) Juan Pablo Domecq et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Importance of Early Weight Changes to Predict Long-Term Weight Gain During Psychotropic Drug Treatment
- (2015) Frederik Vandenberghe et al. JOURNAL OF CLINICAL PSYCHIATRY
- Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment
- (2015) Wei Zheng et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications
- (2015) Carla A. Green et al. Obesity
- Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
- (2015) Hubertus Himmerich et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure
- (2015) Sarah M. Bahr et al. EBioMedicine
- β-Blockers
- (2014) Toni L. Ripley et al. ANNALS OF PHARMACOTHERAPY
- Tissue-specific dysregulation of cortisol regeneration by 11βHSD1 in obesity: has it promised too much?
- (2014) Andreas Stomby et al. DIABETOLOGIA
- GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
- (2014) Ajaykumar N. Sharma et al. METABOLIC BRAIN DISEASE
- Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
- (2014) Sonja K. Billes et al. PHARMACOLOGICAL RESEARCH
- Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
- (2014) Yueshan Hu et al. PLoS One
- A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome
- (2014) Nicole P. Bowles et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis
- (2014) Y. Mizuno et al. SCHIZOPHRENIA BULLETIN
- Molecular pathophysiology of metabolic effects of antipsychotic medications
- (2014) Jacob S. Ballon et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed
- (2014) Tahireh A. Shams et al. Current Psychiatry Reports
- Phentermine/Topiramate for the Treatment of Obesity
- (2013) Steven M Smith et al. ANNALS OF PHARMACOTHERAPY
- Diabetes, obesity and gut microbiota
- (2013) Amandine Everard et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Effects of Low-Dose Prednisolone on Hepatic and Peripheral Insulin Sensitivity, Insulin Secretion, and Abdominal Adiposity in Patients With Inflammatory Rheumatologic Disease
- (2013) Carolyn J. Petersons et al. DIABETES CARE
- Metabolic and endocrine effects of valproic acid chronic treatment
- (2013) Vincenzo Belcastro et al. EPILEPSY RESEARCH
- Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice
- (2013) John W. Newcomer et al. JOURNAL OF CLINICAL PSYCHIATRY
- Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment-A position paper of theThe Obesity Societyand theAmerican Society of Hypertension
- (2013) Lewis Landsberg et al. Obesity
- Weight Considerations in Psychotropic Drug Prescribing and Switching
- (2013) Mehrul Hasnain et al. POSTGRADUATE MEDICINE
- Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
- (2012) Bjørn H Ebdrup et al. BMC Medicine
- Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics
- (2012) Jee-Eun Oh et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis
- (2011) A. E. Pontiroli et al. DIABETES OBESITY & METABOLISM
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
- (2011) T A P Lett et al. MOLECULAR PSYCHIATRY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
- (2011) Alex J. Mitchell et al. SCHIZOPHRENIA BULLETIN
- Fructose consumption: recent results and their potential implications
- (2010) Kimber L. Stanhope et al. Annals of the New York Academy of Sciences
- A β3-Adrenergic-Leptin-Melanocortin Circuit Regulates Behavioral and Metabolic Changes Induced by Chronic Stress
- (2010) Jen-Chieh Chuang et al. BIOLOGICAL PSYCHIATRY
- Obesity following kidney transplantation and steroid avoidance immunosuppression
- (2010) Eric A. Elster et al. CLINICAL TRANSPLANTATION
- Antidepressants and Body Weight
- (2010) Alessandro Serretti et al. JOURNAL OF CLINICAL PSYCHIATRY
- Predictive Value of Early Changes in Triglycerides and Weight for Longer-Term Changes in Metabolic Measures During Olanzapine, Ziprasidone or Aripiprazole Treatment for Schizophrenia and Schizoaffective Disorder
- (2010) Vicki P. Hoffmann et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mifepristone Reduces Weight Gain and Improves Metabolic Abnormalities Associated With Risperidone Treatment in Normal Men
- (2010) Coleman Gross et al. Obesity
- Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications
- (2010) A. Verrotti et al. Obesity Reviews
- Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies
- (2009) H. Verdoux et al. ACTA PSYCHIATRICA SCANDINAVICA
- Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain
- (2009) J. K. Belanoff et al. DIABETES OBESITY & METABOLISM
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
- (2009) Christoph U. Correll JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β
- (2009) C Pavan et al. PHARMACOGENOMICS JOURNAL
- Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour
- (2009) Greg C. Smith et al. SCHIZOPHRENIA RESEARCH
- Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis
- (2008) Peter K. Wung et al. ARTHRITIS AND RHEUMATISM
- Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials
- (2008) Mario Álvarez-Jiménez et al. BRITISH JOURNAL OF PSYCHIATRY
- AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome
- (2008) Mirjam Christ-Crain et al. FASEB JOURNAL
- The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
- (2008) Kirsten Lykkegaard et al. SCHIZOPHRENIA RESEARCH
- Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
- (2008) Gail L. Daumit et al. SCHIZOPHRENIA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started